Weight loss during anthracycline-based treatment of early stage breast cancer (BC) is associated with poorer overall survival (OS). That was a finding of a study by researchers at Heinrich Heine University, Dusseldorf, Germany, and other institutions.
They analyzed the records of 1502 patients in the ongoing ADEBAR trial. Of them, 1177 completed six cycles of chemotherapy. Of the 350 patients (29.7%) who changed weight, 142 (12.1%) lost and 208 (17.7%) gained weight. Patients with weight change >5% showed significantly worse OS (P
=0.0028) and BC-specific survival (BCSS)(P
=0.0258). However, the researchers saw no difference in disease-free survival (P
=0.1917). The difference in OS was limited to patients who lost weight (P=0.0008); patients with weight gain have no significant different OS (P
=0.1246) vs patients with constant weight.